Dexcom Inc
DXCM60.230USD
+1.810+3.10%
Cierre 11/21, 16:00（ET）Cotizaciones retrasadas 15 min
23.49BCap. mercado
32.59P/E TTM
Más Datos de Dexcom Inc Compañía
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Información de Dexcom Inc
Símbolo de cotizaciónDXCM
Nombre de la empresaDexcom Inc
Fecha de salida a bolsaApr 14, 2005
Director ejecutivoMr. Jacob Steven (Jake) Leach
Número de empleados10300
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 14
Dirección6340 Sequence Dr
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92121
Teléfono18582000200
Sitio Webhttps://www.dexcom.com/
Símbolo de cotizaciónDXCM
Fecha de salida a bolsaApr 14, 2005
Director ejecutivoMr. Jacob Steven (Jake) Leach
Ejecutivos de Dexcom Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jacob Steven (Jake) Leach
Mr. Jacob Steven (Jake) Leach
President, Interim Principal Executive Officer, Chief Operating Officer, Director
President, Interim Principal Executive Officer, Chief Operating Officer, Director
294.46K
+6.59%
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Interim Independent Chairman of the Board
Interim Independent Chairman of the Board
62.13K
+4.65%
Mr. Steven R. (Steve) Altman
Mr. Steven R. (Steve) Altman
Independent Director
Independent Director
61.05K
+4.13%
Mr. Richard Alexander Collins
Mr. Richard Alexander Collins
Independent Director
Independent Director
44.38K
+5.82%
Mr. Nicholas (Nick) Augustinos
Mr. Nicholas (Nick) Augustinos
Independent Director
Independent Director
42.13K
+6.12%
Mr. Jereme M. Sylvain
Mr. Jereme M. Sylvain
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
35.33K
-12.01%
Ms. Bridgette P. Heller
Ms. Bridgette P. Heller
Independent Director
Independent Director
27.03K
-3.61%
Mr. Kyle Malady
Mr. Kyle Malady
Independent Director
Independent Director
22.67K
-2.86%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Independent Director
Independent Director
9.04K
+127.87%
Ms. Renee D. Gala
Ms. Renee D. Gala
Independent Director
Independent Director
6.88K
+20.30%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jacob Steven (Jake) Leach
Mr. Jacob Steven (Jake) Leach
President, Interim Principal Executive Officer, Chief Operating Officer, Director
President, Interim Principal Executive Officer, Chief Operating Officer, Director
294.46K
+6.59%
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Interim Independent Chairman of the Board
Interim Independent Chairman of the Board
62.13K
+4.65%
Mr. Steven R. (Steve) Altman
Mr. Steven R. (Steve) Altman
Independent Director
Independent Director
61.05K
+4.13%
Mr. Richard Alexander Collins
Mr. Richard Alexander Collins
Independent Director
Independent Director
44.38K
+5.82%
Mr. Nicholas (Nick) Augustinos
Mr. Nicholas (Nick) Augustinos
Independent Director
Independent Director
42.13K
+6.12%
Mr. Jereme M. Sylvain
Mr. Jereme M. Sylvain
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
35.33K
-12.01%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Distributor
977.80M
84.50%
Direct
179.30M
15.50%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
841.00M
72.68%
Outside of United states
316.10M
27.32%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Distributor
977.80M
84.50%
Direct
179.30M
15.50%
Estadísticas de accionistas
Actualizado: mar., 18 de nov
Actualizado: mar., 18 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
12.63%
BlackRock Institutional Trust Company, N.A.
6.24%
State Street Investment Management (US)
4.32%
Baillie Gifford & Co.
4.07%
Geode Capital Management, L.L.C.
2.81%
Otro
69.92%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
12.63%
BlackRock Institutional Trust Company, N.A.
6.24%
State Street Investment Management (US)
4.32%
Baillie Gifford & Co.
4.07%
Geode Capital Management, L.L.C.
2.81%
Otro
69.92%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
53.29%
Investment Advisor/Hedge Fund
27.90%
Hedge Fund
7.32%
Research Firm
4.05%
Pension Fund
2.14%
Bank and Trust
1.93%
Sovereign Wealth Fund
1.61%
Venture Capital
0.48%
Individual Investor
0.37%
Otro
0.93%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
2166
379.27M
97.24%
-45.06M
2025Q2
2212
390.97M
99.70%
-27.53M
2025Q1
2252
386.55M
98.59%
-25.17M
2024Q4
2220
380.88M
97.47%
-26.96M
2024Q3
2145
382.31M
97.83%
-30.58M
2024Q2
2115
397.02M
99.11%
-4.31M
2024Q1
2093
389.18M
98.33%
-19.87M
2023Q4
2081
398.01M
103.26%
+83.33K
2023Q3
1994
389.89M
100.89%
-11.88M
2023Q2
1952
389.17M
100.78%
-12.73M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
48.15M
12.28%
+859.71K
+1.82%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
24.25M
6.18%
-475.12K
-1.92%
Jun 30, 2025
State Street Investment Management (US)
16.86M
4.3%
+175.27K
+1.05%
Jun 30, 2025
Baillie Gifford & Co.
16.71M
4.26%
+2.53M
+17.81%
Jun 30, 2025
Geode Capital Management, L.L.C.
10.77M
2.75%
+358.62K
+3.45%
Jun 30, 2025
Jennison Associates LLC
11.52M
2.94%
+994.30K
+9.45%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
8.03M
2.05%
-28.35K
-0.35%
Aug 31, 2025
Nuveen LLC
7.30M
1.86%
-549.07K
-7.00%
Jun 30, 2025
MFS Investment Management
6.49M
1.65%
+3.30M
+103.55%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
First Trust Nasdaq Lux Digi Health Solutions ETF
7.15%
Langar Global HealthTech ETF
5.33%
Global X Internet of Things ETF
4.45%
Harbor Health Care ETF
3.85%
Fidelity Digital Health ETF
3.76%
Global X HealthTech ETF
3.67%
iShares U.S. Medical Devices ETF
3.19%
Touchstone Sands Capital US Select Growth ETF
3.06%
Motley Fool Global Opportunities ETF
2.13%
Global X Aging Population ETF
2.02%
Ver más
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción7.15%
Langar Global HealthTech ETF
Proporción5.33%
Global X Internet of Things ETF
Proporción4.45%
Harbor Health Care ETF
Proporción3.85%
Fidelity Digital Health ETF
Proporción3.76%
Global X HealthTech ETF
Proporción3.67%
iShares U.S. Medical Devices ETF
Proporción3.19%
Touchstone Sands Capital US Select Growth ETF
Proporción3.06%
Motley Fool Global Opportunities ETF
Proporción2.13%
Global X Aging Population ETF
Proporción2.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 28, 2022
Split
1→4
Fecha
Tipo
Relación
Mar 28, 2022
Split
1→4
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Dexcom Inc?
Los cinco principales accionistas de Dexcom Inc son:
The Vanguard Group, Inc. posee 48.15M acciones, lo que representa el 12.28% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 24.25M acciones, lo que representa el 6.18% del total de acciones.
State Street Investment Management (US) posee 16.86M acciones, lo que representa el 4.30% del total de acciones.
Baillie Gifford & Co. posee 16.71M acciones, lo que representa el 4.26% del total de acciones.
Geode Capital Management, L.L.C. posee 10.77M acciones, lo que representa el 2.75% del total de acciones.
The Vanguard Group, Inc. posee 48.15M acciones, lo que representa el 12.28% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 24.25M acciones, lo que representa el 6.18% del total de acciones.
State Street Investment Management (US) posee 16.86M acciones, lo que representa el 4.30% del total de acciones.
Baillie Gifford & Co. posee 16.71M acciones, lo que representa el 4.26% del total de acciones.
Geode Capital Management, L.L.C. posee 10.77M acciones, lo que representa el 2.75% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Dexcom Inc?
Los tres principales tipos de accionista de Dexcom Inc son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
¿Cuántas instituciones poseen acciones de Dexcom Inc (DXCM)?
A fecha de 2025Q3, 2166 instituciones poseen acciones de Dexcom Inc, con un valor de mercado combinado de aproximadamente 379.27M, lo que representa el 97.24% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -2.45%.
¿Cuál es la mayor fuente de ganancias de Dexcom Inc?
El FY2025Q2, el segmento empresarial Distributor generó la ganancia más alta para Dexcom Inc, ascendiendo a 977.80M y representando el 84.50% de la ganancia total.
